FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555722368> ?p ?o ?g. }

• W2555722368 abstract "Abstract Abstract 4728 Imatinib mesylate (imatinib) has been widely used clinically for the treatment of CML and Ph-positive ALL patients with tremendous success. However, the effect is limited in advanced stage by rapid development of resistance to imatinib. Tregs play a pivotal role in peripheral tolerance and their impairment results in autoimmune disease and GVHD. Previous studies have revealed that imatinib inhibits the proliferation of several types of immune cells. However, immunomodulatory function of imatinib in CML remains to be elucidated. In the present study, we investigated whether imatinib exerts an immunosuppressive effect on naturally occurring Tregs in T cell responses to CML, especially imatinib-resistant CML. Peripheral blood mononuclear cells were obtained from 5 healthy volunteers with informed consent. CD4+CD25+ and CD4+CD25- T cells were isolated by magnetic cell sorting using human CD4+CD25+ T regulatory cell isolation kit (Miltenyi Biotec). Both CD4+CD25+ and CD4+CD25- T cells, pre-stimulated with anti-CD3 and anti-CD28 monoclonal antibody-coated beads for 2 days, were cultured with increasing doses of imatinib for 3 days and survival of the cells was evaluated by a WST1 tetrazolium assay. Viability decreased at higher concentrations (>10μM) of imatinib. There was no difference in the sensitivity to imatinib between CD4+CD25+ and CD4+CD25- T cells. To examine whether imatinib exerts an inhibitory effect on the proliferation of Tregs, freshly isolated CD4+CD25+ and CD4+CD25- T cells were cultured with varying concentrations of imatinib together with CD3 and CD28 stimulation for 3 days. The proliferation of these cells was inhibited by higher concentrations of imatinib in a similar fashion. Expression of FoxP3 in CD4+CD25+ Tregs was inhibited with 10μM imatinib by apporoximately 70% as shown in Figure 1. Because Treg has been shown to suppress immunity against cancer, a similar inhibitory effect is expected to occur in CML. This prompts us to examine immune responses to CML. For this purpose, we utilized a cell line (TM) established by us from a patient with CML in blastic crisis and another imatinib-resistant cell line (TM-G) generated by culturing TM with increasing concentrations of imatinib. CFSE-labeled CD4+CD25- and CD8+ responder cells were cultured for 5 days with irradiated autologous CD3- antigen presenting cells which were loaded with cell-lysates from either TM or TM-G in the presence or absence of Tregs which were pre-incubated with increasing concentrations of imatinib for 2 days. Proliferation of both CD4+CD25- and CD8+ responder cells were inhibited by Tregs which were not exposed to imatinib. On the other hand, Tregs which were exposed to imatinib had reduced inhibitory effects on the proliferation of responder cells depending on the concentration of imatinib as shown in Figure 2. These results demonstrate the immunomodulatory functions of imtinib in CML and imply that the use of this drug is a potent inhibitor of Tregs in cancer immunotherapy. Disclosures: No relevant conflicts of interest to declare." @default.
• W2555722368 created "2016-11-30" @default.
• W2555722368 creator A5001657741 @default.
• W2555722368 creator A5004999383 @default.
• W2555722368 creator A5006158144 @default.
• W2555722368 creator A5017240065 @default.
• W2555722368 creator A5018073323 @default.
• W2555722368 creator A5038192500 @default.
• W2555722368 creator A5048832660 @default.
• W2555722368 creator A5049803192 @default.
• W2555722368 creator A5054033361 @default.
• W2555722368 creator A5054504614 @default.
• W2555722368 creator A5054830507 @default.
• W2555722368 creator A5055166332 @default.
• W2555722368 creator A5063759141 @default.
• W2555722368 creator A5067046384 @default.
• W2555722368 creator A5080128592 @default.
• W2555722368 creator A5091074660 @default.
• W2555722368 date "2009-11-20" @default.
• W2555722368 modified "2023-09-27" @default.
• W2555722368 title "Imatinib Mesylate Impairs the Function of Human Regulatory T Cells (Tregs) and Reverses the Inhibition of Immune Responses to Imatinib-Resistant CML Cells by Tregs." @default.
• W2555722368 doi "https://doi.org/10.1182/blood.v114.22.4728.4728" @default.
• W2555722368 hasPublicationYear "2009" @default.
• W2555722368 type Work @default.
• W2555722368 sameAs 2555722368 @default.
• W2555722368 citedByCount "0" @default.
• W2555722368 crossrefType "journal-article" @default.
• W2555722368 hasAuthorship W2555722368A5001657741 @default.
• W2555722368 hasAuthorship W2555722368A5004999383 @default.
• W2555722368 hasAuthorship W2555722368A5006158144 @default.
• W2555722368 hasAuthorship W2555722368A5017240065 @default.
• W2555722368 hasAuthorship W2555722368A5018073323 @default.
• W2555722368 hasAuthorship W2555722368A5038192500 @default.
• W2555722368 hasAuthorship W2555722368A5048832660 @default.
• W2555722368 hasAuthorship W2555722368A5049803192 @default.
• W2555722368 hasAuthorship W2555722368A5054033361 @default.
• W2555722368 hasAuthorship W2555722368A5054504614 @default.
• W2555722368 hasAuthorship W2555722368A5054830507 @default.
• W2555722368 hasAuthorship W2555722368A5055166332 @default.
• W2555722368 hasAuthorship W2555722368A5063759141 @default.
• W2555722368 hasAuthorship W2555722368A5067046384 @default.
• W2555722368 hasAuthorship W2555722368A5080128592 @default.
• W2555722368 hasAuthorship W2555722368A5091074660 @default.
• W2555722368 hasConcept C203014093 @default.
• W2555722368 hasConcept C2776090121 @default.
• W2555722368 hasConcept C2777583451 @default.
• W2555722368 hasConcept C2778729363 @default.
• W2555722368 hasConcept C3019892230 @default.
• W2555722368 hasConcept C502942594 @default.
• W2555722368 hasConcept C71924100 @default.
• W2555722368 hasConcept C79484868 @default.
• W2555722368 hasConcept C8891405 @default.
• W2555722368 hasConcept C98274493 @default.
• W2555722368 hasConceptScore W2555722368C203014093 @default.
• W2555722368 hasConceptScore W2555722368C2776090121 @default.
• W2555722368 hasConceptScore W2555722368C2777583451 @default.
• W2555722368 hasConceptScore W2555722368C2778729363 @default.
• W2555722368 hasConceptScore W2555722368C3019892230 @default.
• W2555722368 hasConceptScore W2555722368C502942594 @default.
• W2555722368 hasConceptScore W2555722368C71924100 @default.
• W2555722368 hasConceptScore W2555722368C79484868 @default.
• W2555722368 hasConceptScore W2555722368C8891405 @default.
• W2555722368 hasConceptScore W2555722368C98274493 @default.
• W2555722368 hasLocation W25557223681 @default.
• W2555722368 hasOpenAccess W2555722368 @default.
• W2555722368 hasPrimaryLocation W25557223681 @default.
• W2555722368 hasRelatedWork W2004678195 @default.
• W2555722368 hasRelatedWork W2044781236 @default.
• W2555722368 hasRelatedWork W2547940150 @default.
• W2555722368 hasRelatedWork W2555020818 @default.
• W2555722368 hasRelatedWork W2556815783 @default.
• W2555722368 hasRelatedWork W2562210683 @default.
• W2555722368 hasRelatedWork W2570157274 @default.
• W2555722368 hasRelatedWork W2579201588 @default.
• W2555722368 hasRelatedWork W2584157388 @default.
• W2555722368 hasRelatedWork W2587757802 @default.
• W2555722368 hasRelatedWork W2591685873 @default.
• W2555722368 hasRelatedWork W2613161302 @default.
• W2555722368 hasRelatedWork W2621376045 @default.
• W2555722368 hasRelatedWork W2895148148 @default.
• W2555722368 hasRelatedWork W2979962080 @default.
• W2555722368 hasRelatedWork W2980124093 @default.
• W2555722368 hasRelatedWork W2980261386 @default.
• W2555722368 hasRelatedWork W2989109767 @default.
• W2555722368 hasRelatedWork W2992713492 @default.
• W2555722368 hasRelatedWork W3211186231 @default.
• W2555722368 isParatext "false" @default.
• W2555722368 isRetracted "false" @default.
• W2555722368 magId "2555722368" @default.
• W2555722368 workType "article" @default.